The MMRC is a unique research model that was developed to accelerate the development of novel, cutting-edge treatments for patients afflicted by multiple myeloma by catalyzing, promoting, and facilitating collaborative research between industry and academia. Founded in 2004, the MMRC now stands as an optimal model to fast-track promising myeloma therapies out of the research lab and into clinic where patients can benefit.

The MMRC is comprised of sixteen world-renowned Member Institutions:

• Baylor Charles A. Sammons Cancer Center at Dallas
• Barbara Ann Karmanos Cancer Institute
• City of Hope
• Dana-Farber Cancer Institute
• Emory University's Winship Cancer Institute
• The John Theurer Cancer Center at Hackensack University Medical Center
• Mayo Clinic
• Mount Sinai School of Medicine
• Ohio State University
• Sarah Cannon Research Institute
• University Health Network (Princess Margaret Hospital)
• University of California-San Francisco
• University of Chicago
• University of Michigan
• Virginia Cancer Specialists
• Washington University in St. Louis

At the core of this unique model is the MMRC Tissue Bank, the only resource of its kind that integrates myeloma tissue samples with corresponding genomic and clinical data to enable researchers to rapidly advance research efforts.

Researchers from these institutions are conducting innovative research efforts in three Research Cores that span the most exciting areas of myeloma research:

• Genomics Core
• Validation Core
• Clinical Trials Core

A state-of-the-art Data Bank enables the standardization and sharing of clinical and research data to facilitate research efforts among Consortium researchers and across Member Institutions.

Committed to bringing new treatments to patients as quickly as possible, MMRC research and drug development efforts are highly focused on the robust validation of new and combination therapies and advancing these compounds into high-quality, Phase I and II clinical trials.